Business Context and Reporting Period
This Form 8-K filing by Aileron Therapeutics, Inc. (noted as Rein Therapeutics, Inc. in metadata) covers events occurring on September 5, 2018. The report details significant changes in executive leadership and board composition.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and equity grants.
- Base Salary: $500,000 annualized ($41,666.67 per month) for the new CEO.
- Performance Bonus: Up to 50% of base salary annually (starting 2019); 2018 bonus is pro-rated based on prior and new salary rates.
- Equity Grant: Options to purchase 232,914 shares of common stock, vesting monthly over four years.
- Expense Reimbursement: Up to $4,000 per month for travel and living accommodations.
Material Changes
The primary material change is the appointment of Manuel C. Alves Aivado, M.D., Ph.D., as President and Chief Executive Officer, effective September 6, 2018. Dr. Aivado succeeds John Longenecker, Ph.D., who resigned as President and Interim CEO effective the same date. Dr. Longenecker is expected to remain employed through September 30, 2018. Additionally, Dr. Aivado was elected to the Board of Directors as a Class III director.
Outlook, Risks, and Contingencies
Compensation Contingencies:
- Severance (Standard): 12 months of base salary and COBRA coverage if terminated without Cause or for Good Reason outside of a Change in Control.
- Severance (Change in Control): 18 months of base salary, COBRA coverage, 1.5x target bonus, and full acceleration of unvested equity if terminated without Cause or for Good Reason within 12 months of a Change in Control.
- Indemnification: The Company may be required to indemnify Dr. Aivado for legal expenses, judgments, and fines arising from his service as an officer or director.
Management Commentary: The Board believes Dr. Aivado is qualified due to his extensive knowledge of the Company and significant background in pharmaceutical R&D, including prior roles at Taiho Oncology and GlaxoSmithKline.
Investor Verification Checklist
- Verify the exact closing stock price on September 6, 2018, to determine the exercise price of the 232,914 stock options granted.
- Confirm the specific performance milestones for the discretionary bonus, as these are set by the Board and not detailed in this filing.
- Review the full text of the New Employment Agreement and Severance Agreement, which are filed as exhibits to the subsequent Form 10-Q.
- Monitor the transition period for Dr. Longenecker through September 30, 2018, for any operational impacts.